Sara presented her work on the development of an advanced cell therapy based on antigen-specific tolerogenic dendritic cells (TolDCs) to re-establish immune tolerance in immune-mediated diseases.
IQS at the 2nd Barcelona Blood–Brain Barrier (B4) Conference
https://immutol-horizon.eu/wp-content/uploads/2025/09/Immagine11.jpg 541 722 IMMUTOL IMMUTOL https://immutol-horizon.eu/wp-content/uploads/2025/09/Immagine11.jpg